Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2010 - 2018)

Ani Pharmaceuticals (ANIP) has 9 years of Change in Accured Expenses data on file, last reported at $1.0 million in Q3 2018.

• For the quarter ending Q3 2018, Change in Accured Expenses fell 43.14% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2018 stood at $174000.0 (up 74.0% YoY), and the FY2017 full-year result was $644000.0, down 31.49% from the prior year.
• Change in Accured Expenses rose to $1.0 million in Q3 2018, from -$749000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q3 2017 to a low of -$1.9 million in Q4 2015.
• A 5-year average of $171473.7 and a median of $143000.0 in 2014 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 523.08% in 2015 and surged 45125.0% in 2017, its largest moves.
• Tracing ANIP's Change in Accured Expenses over 5 years: stood at -$630000.0 in 2014, then sank by 198.57% to -$1.9 million in 2015, then climbed by 8.88% to -$1.7 million in 2016, then jumped by 31.74% to -$1.2 million in 2017, then jumped by 187.52% to $1.0 million in 2018.
• Business Quant data shows ANIP's Change in Accured Expenses at $1.0 million in Q3 2018, -$749000.0 in Q2 2018, and $1.1 million in Q1 2018.